Nectar Lifesciences Limited (LUX: NECLF)

Market Cap	87.80M
Revenue (ttm)	178.72M
Net Income (ttm)	1.15M
Shares Out	n/a
EPS (ttm)	0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Nectar Lifesciences

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablet...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 1,686
• Stock Exchange: Luxembourg Stock Exchange
• Ticker Symbol: NECLF

Financial Performance

Financial numbers in INR